Lipoproteins in Diabetes Mellitus

1. Auflage 2014
ISBN: 978-1-4939-3218-4
Verlag: SPRINGER NATURE

Buch, Englisch, 466 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 1226 g

Reihe: Contemporary Diabetes

Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. The epidemic of diabetes mellitus is expected to result in one of the steepest rises in human morbidity and mortality ever observed outside of wartime. Insulin resistance is a hallmark of pre-diabetes and type 2 diabetes mellitus, and is characterized by impaired insulin-signaling transduction. Authoritative and comprehensive, Lipoproteins in Diabetes Mellitus details the many changes wrought by insulin resistance and diabetes mellitus on lipid and lipoprotein metabolism. The book begins by summarizing the various techniques to measure lipoproteins and their subclasses. The mechanisms by which insulin resistance and diabetes mellitus increase risk for atherosclerosis, diabetic retinopathy, and diabetic nephropathy are then explored in detail. Finally, the effects of lifestyle modification and the results of clinical trials using established and investigational drugs are discussed.

An invaluable contribution to the literature, Lipoproteins in Diabetes Mellitus is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It will have a long-lasting and significant effect on the medical management of people with diabetes.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Jenkins, Alicia J.

Toth, Peter P.

Lyons, Timothy J.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Endokrinologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Diabetologie

Inhaltsverzeichnis

Ch1: Laboratory Assessment of Lipoproteins in DiabetesDavid R. SullivanBarry Lewis Ch2: Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin Resistance DiabetesMichael CobblePatrick D. MizeEliot A. Brinton Ch3: Insulin Resistance and AtherosclerosisKamalpreet SinghVasudevan A. Raghavan Ch4: Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 DiabetesThomas D. Dayspring Ch5: Lipoprotein Metabolism and Alterations induced by insulin resistance and diabetesGerald H. TomkinDaphne Owens Ch6: Production and Metabolism of Triglyceride-Rich Lipoproteins in both the Normal and Diabetic States Angela PirilloGiuseppe D. NorataAlberico L. Catapano Ch7: Lipoprotein(a): Structure, Metabolism and PathophysiologyAlicia J. JenkinsKaram M. KostnerGerhard M. Kostner Ch8: Lipoprotein Glycation in Diabetes MellitusAlicia J. JenkinsRichard L. KleinAndrzej S. Januszewski
Ch9: Lipoprotein (LDL and HDL) Oxidation in Diabetes MellitusMarielle KaplanMichael AviramTony Hayek Ch10: The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in DiabetesMaria F. Lopes-VirellaGabriel Virella Ch11: Lipid - Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of DiabetesNarin OsmanPeter J. Little Ch12: Tools for Assessing Lipoprotein Metabolism in Diabetes MellitusRichard L. Klein Ch13: Endothelial Dysfunction and Dyslipidaemia in Type 2 Diabetes: Pathogenesis, Significance and TherapySandra J. HamiltonGerald F. Watts Ch14: Lipoproteins and Diabetic NephropathyVille-Petteri MäkinenNina TolonenPer-Henrik Groop Ch15: Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic RetinopathyMingyuan WuTimothy J. Lyons Ch16: Effects of Lifestyle (Diet, Plant Sterols, Excercise) and Glycemic Control on Lipoporteins in Diabetes Peter Clifton Ch17: About Randomised Clinical Trials Related to Lipoproteins in Diabetes MellitusAnthony KeechAlicia J. JenkinsVal Gebski Ch18: Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic PatientsSeth S. MartinParag H. JoshiSteven R. Jones Ch19: The PPAR System in DiabetesJean Claude AnsquerChristelle Foucher Ch20: Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic PatientsEliot A. Brinton Ch21: Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic PatientsHenry A. TranArthur Z. SchwartzbardJames A. Underberg Ch22: Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes MellitusHarold Bays Ch23: Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes Peter J. LittleAlan ChaitAndrzej S. JanuszewskiAlex BobikDavid O'NealAlicia J. Jenkins

Über Autor(innen)

Alicia Jenkins, MBBS, MD, FRACP, FRCP
University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Oklahoma City, OK, USA Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC
CGH Medical Center, Sterling, IL
University of Illinois College of Medicine, Clinical Family and Community Medicine, Peoria, IL
Michigan State University College of Osteopathic Medicine, Clinical Medicine, East Lansing, MI, USA
Timothy J. Lyons, MD, FRCP
University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Harold Hamm Diabetes Center, Oklahoma City, OK, USA